An interventional study of Radiomics in Endometrial Cancer, Uterine Cancer and Endometrium Tumor, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. Active, not recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-09.
Sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Endometrial Neoplasms with a site in Italy — 70 open to participants now, 87 under way, 16 of them phase 3. Endometrial Neoplasms · Italy.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, this one is the 58th largest by planned enrollment of the 96 interventional ones that give a count, is one of 14 that started in 2021, is one of 19 with no phase, reaches primary completion later than 33 of the 86 other live ones, and was the 49th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →70 of the 139 studies in Endometrial Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
European Institute of Oncology · Sites in Italy
Ages 18+ · Women only
Eikon Therapeutics · Sites in Italy, United States, Australia and 12 more countries
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 21–75 · Women only
Genmab · Sites in Italy, United States, Australia and 16 more countries
Ages 18+ · Women only
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 39 · Phase 3 27 · Phase 4 1
First in 1988; this study’s year is marked. 14 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 290 across the 96 interventional studies, 200 across the 42 observational. Of the 40 that completed or were terminated, 11 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 139 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano is the lead sponsor of 172 studies on the registry; 50 are open to participants now.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano has 5 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
19 of the studies in Endometrial Neoplasms with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT06790004Azienda USL Reggio Emilia - IRCCSEndometrial Carcinoma: Comparison of Surgical Approaches (Laparoscopy vs Laparotomy) | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06963385Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoRadiomics and Molecular Classification in Endometrial Cancer | 2026-12-31 |
Add all 19 to your calendar (.ics) → With an account.
Among the 139 studies in Endometrial Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Molecular/genomic profiling is the most accurate method to assess the prognosis of endometrial cancer patients. Interestingly, the adoption of radiomics showed important results, across various oncologic specialties. Radiomic allows extracting mineable high-dimensional data from clinical images, thus providing a number of noteworthy information of the tumor tissues. We aim to correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk The central hypothesis is that combining radiomic features might allow identifying various classes of risk for endometrial cancer. The rationale for the proposed research is that once validated, radiomics applied to ultrasonographic images would be an effective, innovative, and cheap method for tailor operative and postoperative treatment modality in endometrial cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(i) preoperative endometrial cancer (any histology); (ii) preoperative ultrasonographic examination; (iii) surgical treatment; (iv) age >= 18 years; (v) signed for research purposes.
Exclusion Criteria:
(i) consent withdraw; (ii) lack of available (tumor) tissue for molecular/genomic profiling.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This prospective single-arm observational study. Patients with newly diagnosed endometrial cancer have an ultrasonographic evaluation and radiomic analysis of the ultrasonographic images. Then patients have surgery followed by molecular/genomic evaluation. We correlate radiomic features with molecular/genomic profiling.
Diagnostic Test: Radiomics
To correlate radiomic features obtained from ultrasound images with the molecular/genomic profiling to identify new hallmarks for stratification of endometrial cancer patients into different classes of risk
To detail the mechanism by which radiomic features predict the classification of endometrial cancer into various classes of risk.
Time frame: 1-18 months
Determinate the scaled impact of radiomic features assessed on ultrasonographic images of endometrial tumors.
Time frame: 1-36 months
Assess the intraobserver and interobserver reproducibility of radiomic features on ultrasonographic images of endometrial tumors
Time frame: 19-36 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 71 months is above that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano →